The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

March 18, 2019 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

‘We may find that more & more of our RA patients have, as this common mechanistic theme, autoantibodies to post-translationally modified proteins.’ —David Fox, MD

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • Anti-Drug Antibodies May Affect RA Treatment
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
Explore This Issue
March 2019
Also By This Author
  • Why & How to Pursue Shared Decision Making with Your Patients

The anti-CCP test is also increasingly being used from a research angle. Some prior studies have used sera collected for other purposes to analyze early pre­clinical immune alterations in ACPA-positive patients. These investigations might potentially identify interventions that alter the disease course, especially in the early preclinical period. Dr. Holers notes, “A number of laboratories are interested in identifying individuals who are risk for developing classified RA in the future.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He points out there are several ongoing placebo-controlled double-blind trials around the world and adds, “The expectation is that once there is a success in prevention that is replicable and has the right kind of safety profile associated with the drug, then that will kindle interest in screening to identify at risk individuals in the general population.”

But the research interest in ACPAs in people with preclinical disease goes even more broadly and deeply. Dr. Holers explains, “These laboratories are investigating these individuals’ immune function, their status, their mucosal inflammation and mucosal biology, all with a focus to understand what might be the fundamental cause of RA before you actually get arthritis.” This basic research might eventually yield insights leading to improved rheumatoid arthritis prevention as well as better treatments for fully developed RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Research on PAD inhibitors is also an area of ongoing interest. Such agents would block or diminish citrullination. PAD inhibitors have been successfully used in mouse models of rheumatoid arthritis.11 “PAD inhibitors could be very useful anti-inflammatory agents,” says Dr. Fox. “However, we don’t know if they would be totally safe, because you need citrullination to make NETs, and NETs are probably important in host defense against bacteria. So you’d have to find the sweet spot between inhibiting enough but not too much. But that’s true for all the medicines we use.”

Research is also ongoing into the larger group of antibodies, known as AMPAs, (anti-modified protein antibodies), of which ACPAs are a subtype. Other AMPAs have been found in patients with RA, although their specificity for RA is less well established. These include anti-carbamylated protein antibodies and those against malondialdehyde–acetaldehyde-modified epitopes.9 Dr. Holers notes, “They are not used clinically yet, but there is work being done to convert those to clinical tests.” The idea is that some patients currently classified as seronegative may be positive for specific AMPAs that contribute to disease pathophysiology.

Work further investigating these AMPAs may help us better categorize and treat subsets of RA that exist on a clinical spectrum of disease with some potentially distinct pathophysiological processes. “The total universe of post-translational modifications of proteins that give rise to autoantibodies is gradually expanding,” notes Dr. Fox. “In the end we may find that more and more of our RA patients have, as this common mechanistic theme, autoantibodies to post-translationally modified proteins.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“I think the ACPA system is very important because it brings together so many different threads of fascinating science,” says Dr. Holers.

Looking back at the first paper describing these autoantibodies, he notes, “You had this very simple observation in 1964, and from that there’s been exponential growth in publications related to citrullination and ACPAs and greatly expanding interest in it. We are also looking at the possibility to use it as a preclinical diagnostic test for prevention. From this modest beginning, this incredible juggernaut of work has evolved.”

He concludes, “I think as people look back on the history of rheumatology and RA, the discovery and characterization of the ACPA system is going to be one of the fundamentally important findings in the field that will have lasting impact.” 

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: anti-citrullinated protein antibody (ACPA), Lost & FoundIssue: March 2019

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • Anti-Drug Antibodies May Affect RA Treatment
  • Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus
  • Antibodies Can Spot RA in the General Population

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.